PROVE2: Phase II study of VX950 (telaprevir) in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis

被引：0
|
作者：
Hezode, Christophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Pol, Stanislas
Goeser, Tobias
Bronowicki, Jean-Pierre
Gharakhanian, Shahin
Devonish, Desiree
Kauffman, Robert
Alam, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
机构：
[1] Hop Henri Mondor, AP HP, Hepatogastroenterol Serv, F-94010 Creteil, France
[2] Med Univ Vienna, Vienna, Austria
[3] Royal Free Hosp, Ctr Hepatol, London NW3 2QG, England
[4] Necker Cochin Hosp, AP HP, Liver Unit, Paris, France
[5] Univ Cologne, Cologne, Germany
[6] Nancy Univ Hosp Ctr, CHU, Nancy, France
[7] Vertex Pharmaceut Inc, Med Dev Grp, Cambridge, MA USA
[8] Hop Henri Mondor, AP HP, Dept Bacterol & Virol, F-94010 Creteil, France
[9] Saarland Univ Hosp, Internal Med Clin 2, Homburg, Germany
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
80
引用
收藏
页码：268A / 269A
页数：2
相关论文
共 50 条
  • [1] Prove2 study: Treatment of chronic hepatitis C with telaprevir (TVR)in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results
    Hezode, Christophe
    Ferenci, Peter
    Dusheiko, Geoffrey M.
    Tran, Albert
    Grange, Jean-Didier
    Mathurin, Philippe
    Schmidt, Wolfgang E.
    Diepolder, Helmut
    Marcellin, Patrick
    Wedemeyer, Heiner
    Forestier, Nicole
    Mangels, Wendy
    Gharakhanian, Shahin
    Kauffman, Robert S.
    Alam, John
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    GASTROENTEROLOGY, 2008, 134 (04) : A755 - A755
  • [2] Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: Further interim analysis results of the PROVE2 study
    Dusheiko, G. M.
    Hezode, C.
    Pol, S.
    Goeser, T.
    Bronowicki, J. -P.
    Bourliere, M.
    Buggisch, P.
    Serfaty, L.
    Berg, T.
    Couzige, P.
    Benhamou, Y.
    Forestier, N.
    Bengtsson, L.
    Gharakhanian, S.
    Kauffman, R.
    Alam, J.
    Ferenci, P.
    Pawlotsky, J. -M.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S26 - S26
  • [3] TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C: FINAL RESULTS OF THE PROVE2 STUDY
    Zeuzem, Stefan
    Hezode, Chritophe
    Ferenci, Peter
    Dusheiko, Geoffrey M.
    Alves, Katia
    Bengtsson, Leif
    Gharakhanian, Shahin
    Kauffman, Robert
    Alam, John J.
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2008, 48 (04) : 418A - 419A
  • [4] Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon α-2a and ribavirin in previously untreated subjects with hepatitis C
    McHutchison, J. G.
    Everson, G. T.
    Gordo, S.
    Jacobson, R.
    Kauffman, R.
    McNair, L.
    Muir, A.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S296 - S296
  • [5] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Jacobson, Ira M.
    Everson, Gregory T.
    Gordon, Stuart C.
    Kauffman, Robert
    McNair, Lindsay
    Muir, Andrew
    McHutchison, John G.
    HEPATOLOGY, 2007, 46 (04) : 315A - 316A
  • [6] Prove1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Everson, Gregory T.
    Jacobson, Ira M.
    Gordon, Stuart C.
    McHutchison, John G.
    Kaufman, Robert
    McNair, Lindsay
    Muir, Andrew
    GASTROENTEROLOGY, 2008, 134 (04) : A758 - A758
  • [7] Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Forestier, Nicole
    Reesink, Hendrik W.
    Weegink, Christine J.
    McNair, Lindsay
    Kieffer, Tara L.
    Chu, Hui-May
    Purdy, Susan
    Jansen, Peter L. M.
    Zeuzem, Stefan
    HEPATOLOGY, 2007, 46 (03) : 640 - 648
  • [8] Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Mchutchison, J. G.
    Everson, G. T.
    Gordon, S. C.
    Jacobson, I.
    Kauffinan, R.
    McNair, L.
    Muir, A.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S4 - S4
  • [9] Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 157 - 159
  • [10] LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY
    Zeuzem, Stefan
    Sulkowski, Mark S.
    Zoulim, Fabien
    Sherman, Kenneth E.
    Alberti, Alfredo
    Wei, L. J.
    van Baelen, Ben
    Sullivan, James
    Kieffer, Tara L.
    De Meyer, Sandra
    Picchio, Gaston
    Tomaka, Frank
    Graham, Camilla S.
    McHutchison, John G.
    HEPATOLOGY, 2010, 52 (04) : 436A - 436A
12345